ACRX - AcelRx Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

704.5K

Cash

7.41M

Avg Qtr Burn

-5.309M

Short % of Float

6.77%

Insider Ownership

0.94%

Institutional Own.

10.10%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DSUVIA (sufentanil) Details Post operative acute pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nafamostat (Niyad™) Details Medical device	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zalviso US (sufentanil) Details Post operative acute pain	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.